http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102416167-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_57fa60a0cac09d94577be5413e9c1e30 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 |
| filingDate | 2011-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a9de4f28b3f793ad628b0521b9cdd2c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_724943c03ef2d879a968032e62658581 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a380cbba05310f5f0336eb53b02a9e7a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4c8d803efebcfed8f73e034df226da7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28f76bbc531ba04e129df13f63b1e10e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a55805bc5663e452dd7b21fb390eee00 |
| publicationDate | 2013-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102416167-B |
| titleOfInvention | Aerosol inhalant containing interferon alpha and terbutaline sulfate |
| abstract | The invention belongs to the field of medicinal compositions for resisting virus, and relates to an aerosol inhalant containing interferon alpha and terbutaline sulfate. The aerosol inhalant contains a therapeutically effective amount of interferon alpha, a therapeutically effective amount of terbutaline sulfate and an appropriate amount of pharmaceutic auxiliary materials; preferably, single dose of the aerosol inhalant contains 2.5 to 30 mu g of interferon alpha, 0.5 to 2 mg of terbutaline sulfate, and an appropriate amount of pharmaceutic auxiliary materials; and more preferably, single dose of the aerosol inhalant contains 10 to 20 mu g of interferon alpha, 1 to 1.5mg of terbutaline sulfate and an appropriate amount of pharmaceutic auxiliary materials. Compared with the interferon alpha or the terbutaline sulfate, the aerosol inhalant containing the interferon alpha and the terbutaline sulfate has the advantages that the effect of treating viral pneumonia can be improved obviously. |
| priorityDate | 2011-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 84.